Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia

doi:10.4240/wjgs.v8.i12.792

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7346)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

407

WORD

272

HTML

3716

Figures (1-1)

229

Sum=4624

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1073

Download

1649

Sum=2722

Dec 27, 2016 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastrointest Surg. Dec 27, 2016; 8(12): 792-795
Published online Dec 27, 2016. doi: 10.4240/wjgs.v8.i12.792

Full Size Figure Download Figure

Figure 1 Hemoglobin trend. Hemoglobin trend before and after initiation of bevacizumab 5 mg/kg every other week starting in April 2015.

Citation: Ou G, Galorport C, Enns R. Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia. World J Gastrointest Surg 2016; 8(12): 792-795
URL: https://www.wjgnet.com/1948-9366/full/v8/i12/792.htm
DOI: https://dx.doi.org/10.4240/wjgs.v8.i12.792